Filing summary
Company and period: The supplied filing is Sunshine Heart, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2013—not a filing under the name Nuwellis, Inc. Sunshine Heart was developing the C-Pulse Heart Assist System for heart failure; it reported no product revenue in the periods presented.
Financial results and position
| Metric | Q2 2013 | Q2 2012 | Six months 2013 | Six months 2012 |
|---|---|---|---|---|
| Net sales | $0 | $0 | $0 | $0 |
| Operating expenses | $5.300 million | $3.356 million | $9.702 million | $7.462 million |
| Operating loss | $5.300 million | $3.356 million | $9.702 million | $7.462 million |
| Net loss | $4.220 million | $2.622 million | $8.619 million | $6.703 million |
| Loss per share, basic and diluted | $0.35 | $0.42 | $0.81 | $1.08 |
| Operating cash used | — | $7.571 million | $6.815 million |
Expenses and losses increased year over year as the company expanded infrastructure and clinical-trial support. Q2 SG&A rose 37.0% to $2.150 million and R&D rose 76.3% to $3.150 million. For the first half, SG&A increased 17.6% to $4.126 million and R&D increased 41.1% to $5.576 million. The company had no gross margin to report because sales were zero.
At June 30, 2013, cash and cash equivalents were $21.526 million, up from $14.224 million at year-end 2012. Total assets were $22.643 million; current liabilities and total liabilities were both $2.250 million, with no debt reported. Current assets of $22.230 million exceeded current liabilities. Stockholders’ equity was $20.393 million and accumulated deficit was $87.873 million. First-half investing cash use was $17,000; financing provided $14.910 million, primarily from stock sales.
Changes, outlook and risks
- The company raised approximately $14.036 million net in an April 2013 public offering of 2.875 million shares at $5.25 per share. It also received $14.910 million net from common-stock sales in the first half overall.
- A January 2013 agreement allows Aspire Capital to purchase up to $25 million of common stock over two years, subject to terms and limits. By June 30, the company had sold 146,886 shares to Aspire Capital, in addition to 80,257 commitment shares.
- The company had FDA approval to conduct a U.S. pivotal trial and expected enrollment to begin in the second half of 2013. Enrollment in a European post-market trial began in Q2 2013; the company also had CE Mark approval. Commercial sales and meaningful revenue remained uncertain.
- Management expected operating expenses to remain above prior-year levels as clinical activity and staffing expanded. It expected minimal revenue until European reimbursement is established and the U.S. pivotal trial begins.
- Management stated existing cash and potential Aspire Capital proceeds were expected to cover anticipated needs for at least 12 months, but additional funding would be required to complete the pivotal trial. The filing warns that inability to raise capital or successfully develop and commercialize the product could threaten the company’s ability to continue as a going concern.
- The $1.077 million income-tax benefit reflected an Australian R&D tax-credit refund received in Q2. The company had not completed the relevant Australian tax return for the year ended June 30, 2013 and had not recognized a benefit for that period.
- The company reported effective disclosure controls and no material changes in internal control over financial reporting. It reported no off-balance-sheet arrangements or material capital-expenditure commitments.
Important facts for investors to verify
- Confirm the issuer identity: the supplied 10-Q is for Sunshine Heart, Inc., despite the request metadata naming Nuwellis, Inc.
- Check subsequent filings for actual pivotal-trial enrollment, regulatory progress, clinical outcomes, and European reimbursement or sales.
- Verify cash runway, trial costs, and any later financing; the stated 12-month liquidity expectation depended partly on potential financing and did not cover completion of the pivotal trial.
- Review dilution exposure from the Aspire Capital arrangement, outstanding warrants and options, and future capital raises.
- Assess the sustainability and timing of Australian R&D tax-credit refunds; the filing says future refunds may decline and the 2013-period amount was not yet determined.